Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

Phase 2 Unknown 100 enrolled Jiangsu Cancer Institute & Hospital

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective is to investigate the efficacy and safety of raltitrexed-based chemotherapy plus bevacizumab in the treatment of advanced colorectal cancer

Timeline

Start: 2017-02-15
Primary completion: 2022-08-15
Completion: 2023-02-15

Publications

Li S, Li X, Zhu Q, Gao J, Zhu C, Zhu L. Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial. Cancer Control. 2024 Jan-Dec;31:10732748241275012. doi: 10.1177/10732748241275012.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	75 mg/kg	Intravenous
Subject	Irinotecan	Small molecule	250 mg/m2	Intravenous
Subject	Oxaliplatin	Small molecule	130 mg/m2	Intravenous
Subject	Raltitrexed	Small molecule	3 mg/m2	Intravenous

Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

Summary

Timeline

Publications

Drugs

Indications